HER2 (erbB-2)-targeted effects of the ϖ-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the «fat features» of the «Mediterranean diet» as an «anti-HER2 cocktail»
- 201 Downloads
Data derived from epidemiological and experimental studies suggest that alphalinolenic acid (ALA; 18:3n-3), the main ϖ-3 polyunsaturated fatty acid (PUFA) present in the Western diet, may have protective effects in breast cancer risk and metastatic progression. A recent pilot clinical trial assessing the effects of ALA-rich dietary flaxseed on tumor biological markers in postmenopausal patients with primary breast cancer demonstrated significant reductions in tumor growth and in HER2 (erbB-2) oncogene expression.
The molecular mechanism by which ALA inhibits breast cancer cell growth and metastasis formation may involve a direct regulation of HER2, a well-characterized oncogene playing a key role in the etiology, progression and response to some chemo- and endocrine therapies in approximately 20% of breast carcinomas.
Using HER2-specific ELISA, flow cytometry, immunofluorescence microscopy, Western blotting, RT-PCR and HER2 promoter-reporter analyses, we characterized the effects of exogenous supplementation with ALA on the expression of HER2 oncogene, a master key player in the onset and metastasis formation of breast cancer disease. Metabolic status (MTT) assays were performed to evaluate the nature of the cytotoxic interaction between ALA and the humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin®). To study these issues we used BT-474 and SKBr-3 breast cancer cells, which naturally exhibit amplification of the HER2 oncogene.
ALA treatment dramatically suppressed the expression of HER2-coded p185Her-2/neu oncoprotein as determined by ELISA, flow cytometry, immunofluorescence microscopy and immunoblotting techniques. Interestingly, ALA-induced down-regulation of p185Her-2/neu correlated with a transciptional response as no HER2 mRNA signal could be detected by RT-PCR upon treatment with optimal concentrations of ALA (up to 20 μM). Consistent with these findings, ALA exposure was found to dramatically repress the activity of a Luciferase reporter gene driven by the HER2 promoter. Moreover, the nature of the cytotoxic interaction between ALA and trastuzumab (Herceptin®) revealed a significant synergism as assessed by MTT-based cell viability assays.
i) These findigns reveal that the ω-3 PUFA ALA suppresses overexpression of HER2 oncogene at the transcriptional level, which, in turn, interacts synergistically with anti-HER2 trastuzumab-based immunotherapy.ii) Our results molecularly support a recent randomized double-blind placebo-controlled clinical trial suggesting that ALA may be a potential dietary alternative or adjunct to currently used drugs in the management of HER2-positive breast carcinomas.iii) Considering our previous findings demonstrating the «HER2 upregulatory actions» of the ω-6 PUFA linolenic acid (LA; 18:2n-6) and the «HER2 down-regulatory actions» of the ω-3 PUFA docosahexaenoic acid (DHA; 22:6n-3) and of the ω-9 monounsaturated fatty acid oleic acid (OA; 18:1n-9), it is reasonable to suggest that a low ω-6/ω-3 PUFA ratio and elevated MUFA levels, the two prominent «fat features» of the «Mediterranean diet», should be extremely efficient at blocking HER2 expression in breast cancer cells.
KeywordsBreast Cancer Breast Cancer Cell Trastuzumab Mediterranean Diet PUFA Ratio
Unable to display preview. Download preview PDF.
- 2.Klein V, Chajes V, Germain E, et al. Low alpha-linolenic acid content of adipose tissue is associated with an increased risk of breast cancer. Eur J Cancer. 2000;56: 555–40.Google Scholar
- 3.Kamano K, Okuyama H, Konishi R, Nagasawa H. Effects of a high-linoleate and high-alpha-linolenate on spontaneous mammary tumorigenesis in mice. Anti-cancer Res. 1989;9:1903–8.Google Scholar
- 4.Fritsche KL, Johnston PV. Effect of dietary alpha-linolenic acid on growth, metastasis, fatty acid profile and prostaglandin production of two murine mammary adenocarcinomas. J Nutr. 1999;120:1601–9.Google Scholar
- 5.Hirose M, Masuda A, Ito N, Kamano K, Okuyama H. Effects of dietary perilla oil, soybean oil and safflower oil on 7,12-dimethylbenz(a) anthracene (DMBA) and 1,2-domethylhydrazine (DMH)-induced mammary gland and colon carcinogenesis in female SD rats. Carcinogenesis. 1990; 11:731–5.PubMedCrossRefGoogle Scholar
- 6.Munoz SF, Silva RA, Lamarque A, Guzmán CA, Eynard AR. Protective capability of dietary Zizyphus mistol seed oil, rich in 18/3 n−3, on the development of two murine mammary gland adenocarcinomas with high and low metastatic potential. Prostaglandins Leukot Essent Fatty Acids. 1995;53:135–8.PubMedCrossRefGoogle Scholar
- 16.Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and-nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol. 2002;15:116–24.PubMedCrossRefGoogle Scholar
- 20.Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62:4152–41.Google Scholar
- 26.Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48.PubMedGoogle Scholar
- 28.Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001;544:785–92.Google Scholar
- 33.Pégorier JP, Le May C, Girard J. Control of gene expression by fatty acids. J Nutr. 2004;154:2444S-9S.Google Scholar
- 35.Menéndez JA, Lupu R, Colomer R. Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22∶6n−3) synergistically enhances taxanes cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev. 2005;14:263–70.PubMedCrossRefGoogle Scholar
- 36.Menéndez JA, Vellón L, Colomer R, Lupu R. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. Ann Oncol. 2005;16:359–71.PubMedCrossRefGoogle Scholar
- 38.Menéndez JA, Papadimitropoulou A, Vellón L, Colomer R, Lupu R. A genomic explanation connecting “Mediterranean diet”, olive oil and cancer: Oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory “PEA3 transcription factor-PEA 3 DNA binding site” complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells. Eur J Cancer. 2006 Jan 4 [Epub ahead of print].Google Scholar
- 39.Menéndez JA, Lupu R. RESPONSE: Re: Effect of-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene. J Natl Cancer Inst. 2006;98:718–20.Google Scholar